Cognition Therapeutics, Inc.

Cognition Therapeutics is a clinical-stage neuroscience company focused on developing oral medications to treat neurodegenerative and neuro-ophthalmic disorders. Their primary focus is on Alzheimer’s disease, dementia with Lewy bodies (DLB), and dry age-related macular degeneration (dry AMD). Cognition Therapeutics is advancing the development of an oral medication, CT1812, which is currently in separate Phase 2 clinical trials for these diseases. CT1812 works by targeting the sigma-2 receptor, a "housekeeping" receptor that regulates key cellular processes like autophagy and protein trafficking. This approach aims to protect neurons in the brain and retina from the damaging effects of toxic proteins.

Cognition Therapeutics is driven by a mission to develop safe, effective, and easy-to-administer treatment options that slow the progression of these life-altering diseases. They have a strong commitment to research and development, as evidenced by their ongoing clinical trials and partnerships with leading research institutions. Their efforts are supported by grants from the National Institute of Aging (NIA) and other organizations, demonstrating their dedication to advancing scientific understanding and finding solutions for patients suffering from neurodegenerative diseases.

Cognition Therapeutics offers a variety of flexible work options, including remote work and flexible hours, which enables employees to achieve a healthy work-life balance and meet personal needs. The company actively promotes collaboration and recognizes the value of personal responsibility and accountability, contributing to a positive and supportive workplace.

Cognition Therapeutics is a clinical-stage neuroscience company dedicated to developing oral medications for the treatment of neurodegenerative and neuro-ophthalmic disorders. Driven by the significant impact of Alzheimer's disease, dementia with Lewy bodies, and dry age-related macular degeneration, they are committed to developing safe, effective, and easily administered treatment options that slow the progression of these life-altering diseases.

Cognition Therapeutics promotes a culture of open collaboration, scientific rigor, and a shared commitment to finding solutions for neurodegenerative diseases. They value inclusivity, drive, transparency, and balance, encouraging employees to be resourceful, persistent, and supportive of one another. They foster a respectful and open workplace where all team members are invited, heard, and appreciated, and where personal responsibility and courageous, innovative contributions are recognized and rewarded.

Cognition Therapeutics, Inc. is committed to fostering a diverse, equitable, and inclusive workplace. They recognize the value brought by small and minority businesses, veteran-owned businesses, and women’s business enterprises and actively encourage their participation in contracting opportunities. They also emphasize open collaboration and scientific rigor, striving to create an honest, respectful, and open workplace where all team members are invited, heard, and appreciated.